8. Rajiv De Silva

Endo's former CEO Rajiv de Silva earned more than $19 million in 2016 pay.

Rajiv De Silva
Former CEO, Endo
2016 compensation: $19.18 million

Endo was struggling when CEO Rajiv de Silva departed last September, turning the reins over to current chief Paul Campanelli. But that didn’t stop de Silva from tallying more than $19 million in 2016 pay.

De Silva scored $19.18 million for helming Endo for less than 10 months last year, a sum that nearly doubled the $10.91 million he had pocketed the year before. On top of a base salary of $840,337, Endo handed him more than $10 million in share awards and $2.5 million in options.

De Silva also nabbed more than $5.6 million in other compensation—most of which came in the form of $5.2 million in severance pay. Also included: Endo forked over $94,932 rather than give de Silva 30 days' notice that he'd be terminated, and paid $250,000 for his accrued vacation.

De Silva’s golden parachute isn’t as big as it might have been had Endo’s shares performed better, though. His options are valueless today, but theoretically could regain value if Endo’s shares take an upturn.

Lately, however, investors haven’t had a whole lot to be excited about. In late February, the company recorded a $3.5 billion writedown, thanks to its suffering generics unit; that event followed three layoffs announcements and a slew of executive exits, including De Silva’s.

8. Rajiv De Silva

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.